Gilvetmab: A Breakthrough Immunotherapy for Canine Cancer
Merck Animal Health has introduced a groundbreaking immunotherapy for canine cancer called gilvetmab. This checkpoint inhibitor specifically designed for dogs targets the PD-1 protein, reactivating.